2019 Videos Archives

AMP 2019 Video Series Part 4 of 4

Invivoscribe Marketing2022-05-25T03:00:59+00:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP 2019 Video Series Part 3 of 4

Invivoscribe Marketing2022-05-25T03:00:59+00:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP 2019 Video Series Part 2 of 4

Invivoscribe Marketing2022-05-25T03:00:59+00:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP 2019 Video Series Part 1 of 4

Invivoscribe Marketing2022-05-25T03:01:00+00:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Invivoscribe – EHA 2019: Part 3 of 3

Invivoscribe Marketing2022-05-25T03:01:00+00:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Invivoscribe – EHA 2019: Part 2 of 3

Invivoscribe Marketing2022-05-25T03:01:00+00:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Invivoscribe – EHA 2019: Part 1 of 3

Invivoscribe Marketing2022-05-25T03:01:00+00:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Invivoscribe – ASCO – LeukoStrat CDx FLT3 Mutation Assay

Invivoscribe Marketing2022-05-25T03:01:00+00:00June 1st, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 4 of 4

Invivoscribe Marketing2022-05-25T03:01:01+00:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 3 of 4

Invivoscribe Marketing2022-05-25T03:01:01+00:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 2 of 4

Invivoscribe Marketing2022-05-25T03:01:01+00:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 1 of 4

Invivoscribe Marketing2022-05-25T03:01:01+00:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

AMP 2019 Video Series Part 4 of 4

AMP 2019 Video Series Part 3 of 4

AMP 2019 Video Series Part 2 of 4

AMP 2019 Video Series Part 1 of 4

Invivoscribe – EHA 2019: Part 3 of 3

Invivoscribe – EHA 2019: Part 2 of 3

Invivoscribe – EHA 2019: Part 1 of 3

Invivoscribe – ASCO – LeukoStrat CDx FLT3 Mutation Assay

AMP Global 2019 Video Series Part 4 of 4

AMP Global 2019 Video Series Part 3 of 4

AMP Global 2019 Video Series Part 2 of 4

AMP Global 2019 Video Series Part 1 of 4

Title

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing